MRK Q3 2026 Earnings Analysis
Merck delivered Q3 2026 revenue of $18.1B (+5%), raised FY2026 EPS guidance to $2.77-$2.82, and achieved major Phase 3 wins for sac-TMT and entismodigene, positioning the company well beyond KEYTRUDA's loss of exclusivity.
Key Metrics
Key Takeaways
- Q3 revenue $18.1B (+5%) driven by WINREVAIR (+94% to $694M), KEYTRUDA (+6% to $8.6B), Gardasil (+14% to $2B).
- FY2026 EPS $2.77-$2.82 guidance; sac-TMT and entismodigene Phase 3 data strengthen confidence beyond KEYTRUDA LOE.
- 2027 faces $2B+ headwinds from generics; offset by new launches. Raising $70B mid-2030s revenue target.
Listen On
Available In
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.
And I'm Jordan. Today we're diving into Merck's third quarter 2026 results, reported this past Thursday.
Before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Good to have that squared away. So Alex, Merck's a company everyone's watching right now because of the Keytruda patent cliff looming. What'd the quarter actually look like?
Solid, honestly. Revenue came in at $18.1 billion, up 5% year-over-year, or 4% excluding currency effects. And they actually narrowed and raised the midpoint of their full-year guidance — now expecting $66.8 to $67.3 billion in revenue and EPS of $2.77 to $2.82.
That's a good sign. Companies don't usually raise guidance if they're nervous about the quarter. Let's talk Keytruda specifically, since that's the elephant in the room.
Right, the Keytruda franchise — including the newer subcutaneous version, Keytruda Qlex — grew 6% to $8.6 billion. Still their biggest product by a mile. But management was candid: they're now approaching peak revenues in certain indications, and growth is moderating as they've basically saturated the eligible patient population.
And that subcutaneous version, Qlex, is actually really interesting as its own story. $830 million in sales this quarter, and there's litigation drama in Europe — a Dutch court issued an injunction over hyaluronidase IP that's blocking sales in several smaller European markets.
Yeah, but CEO Robert Davis was pretty firm that this doesn't change their confidence. The U.S. business is humming — they're targeting 30-40% subcutaneous adoption by end of 2027, and the affected European markets are described as lower-volume anyway.
Okay, so that's the "today" story. But the real headline for me is what they said about 2027 — because that's when the real Keytruda cliff pressure, plus generic competition for Bridion and Januvia, starts biting.
CFO Caroline Litchfield called it directly: more than $2 billion in headwinds next year from generics hitting Bridion, the Januvia family, and Adempas. Plus continued Keytruda moderation and some German pricing policy pressure.
But — and this is the part I think investors should really sit with — she described 2027 as "a year of investment," not decline. They're framing the whole Keytruda loss-of-exclusivity period as more of a "hill" in revenue rather than a cliff, with earnings expected to largely mirror that shallow dip and then resume growth.
That's the bet they're making. And it's backed by what might be the most exciting part of this whole call — the pipeline news out of the ESMO oncology conference last weekend.
Walk us through it, because there were a lot of acronyms flying around.
The biggest one: sac-TMT, their antibody-drug conjugate, showed nearly a 7-month improvement in median overall survival for endometrial cancer patients compared to chemo alone. That's a disease with rising incidence and a really poor prognosis, so that's meaningful.
And then there's entismodigene — the individualized mRNA cancer vaccine they're developing with Moderna. This one actually got some strong outside validation.
Right, Dean Li, their research chief, quoted oncologist Antoni Ribas calling the melanoma data "a landmark in cancer drug development." It showed meaningful improvements in recurrence-free survival when combined with Keytruda in resected melanoma patients. They're now talking with the FDA about filing it.
What struck me is management explicitly said this product's commercial profile turned out better than what they'd originally baked into their long-term targets.
Which ties into the bigger number everyone's anchoring to — that $70 billion revenue opportunity by the mid-2030s that Robert Davis has talked about before. On this call, an analyst from Goldman Sachs asked him point blank whether that number is still intact.
And his answer was basically "more confident, not less" — he noted that number doesn't even include their recent Prometheus acquisition, doesn't fully credit their PD-1/VEGF bispecific combo therapy, and doesn't reflect the upgraded profile for entismodigene. So if anything, there's upside to that target.
Let's not forget WINREVAIR either — their pulmonary arterial hypertension drug. Sales were up 94% to $694 million. They're expanding it into a new patient population with a Phase 3 trial called CORAAL, targeting a form of pulmonary hypertension tied to heart failure that currently has no approved treatment.
And then there's Lipfendra, the new cholesterol drug — early days, but they reported over 11,000 prescriptions from more than 6,500 prescribers in just the quarter, with most coming from patients adding it onto existing therapy rather than switching off injectables. That's exactly the uptake pattern they wanted to see.
So pulling it together — what's the investor takeaway here?
I'd frame it this way: this was a "trust the process" quarter. The near-term numbers were solid, guidance went up, but the real story is Merck trying to prove — card by card, as Davis put it — that their pipeline can backfill the Keytruda cliff before it even becomes a real cliff. Oncology diversification through sac-TMT and the cancer vaccine, cardiovascular expansion through WINREVAIR, and new immunology and ophthalmology shots on goal all matter here.
And the risks are real too — generic erosion starting in 2027, vaccine hesitancy headwinds on Gardasil, ongoing litigation on Qlex in Europe, and plenty of binary clinical readouts still to come over the next 12-24 months.
Before we sign off — everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Well said. Looking ahead, the next big catalysts to watch are the ATLAS UC readout for tultokibart, the Barolo ophthalmology trial results, and more sac-TMT and entismodigene regulatory filings. Merck's betting big that science can outrun the patent cliff — we'll be watching to see if the cards keep turning their way.
This has been Beta Finch — thanks for listening.
See you next time.